Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 736 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... September 23, 2025 Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... September 15, 2023 Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... July 26, 2023 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 Load more HOT NEWS Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... EMA Recommends Granting a Marketing Authorisation for Relugolix EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
